Dyslipidaemia-Add-on Therapy — EECC MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: E — Add ezetimibe
This patient has established ASCVD after a prior myocardial infarction and remains above the stated LDL-C target despite high-intensity statin therapy with rosuvastatin 20 mg. In UK practice, the next non-statin LDL-lowering drug to add is ezetimibe, which inhibits intestinal cholesterol absorption and is recommended by NICE as an additional lipid-lowering option when the secondary-prevention lipid target is not met on the maximum tolerated statin; NICE also states that ezetimibe may be considered in addition to maximum tolerated statin therapy to reduce CVD risk further. Fibrates and omega-3 ethyl esters are not used to reach LDL-C targets, niacin is not recommended, and PCSK9 inhibitors are generally considered after optimisation with statin plus ezetimibe and according to NICE technology-appraisal criteria rather than as the first add-on here.
Reference: NICE Guideline NG238: Cardiovascular disease: risk assessment and reduction, including lipid modification; recommendations 1.7.1, 1.7.9 and 1.7.10, updated December 2023. https://www.nice.org.uk/guidance/ng238/chapter/recommendations